Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Income Statement

Financials in millions USD. Fiscal year is May - April.

Year Ending	TTM	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020	Apr 30, 2019
Selling, General & Admin	4.47	7.42	7.12	3.64	3.35	1.31
Research & Development	7.92	7.45	5.2	1.31	1.07	3.7
Operating Expenses	12.39	14.87	12.32	4.95	4.42	5.01
Operating Income	-12.39	-14.87	-12.32	-4.95	-4.42	-5.01
Interest Expense	-0.01	-0.01	-0.05	-0.16	-	-
Interest & Investment Income	-	-	-	0	0.01	0.15
EBT Excluding Unusual Items	-12.4	-14.88	-12.37	-5.11	-4.41	-4.86
Other Unusual Items	-	-	0	0.06	-	-
Pretax Income	-12.4	-14.88	-12.36	-5.05	-4.41	-4.86
Net Income	-12.4	-14.88	-12.36	-5.05	-4.41	-4.86
Net Income to Common	-12.4	-14.88	-12.36	-5.05	-4.41	-4.86
Shares Outstanding (Basic)	1	1	1	0	0	0
Shares Outstanding (Diluted)	1	1	1	0	0	0
Shares Change (YoY)	4.79%	9.45%	22.64%	1.96%	21.09%	29.64%
EPS (Basic)	-18.63	-22.89	-20.81	-10.42	-9.28	-12.40
EPS (Diluted)	-18.63	-22.89	-20.81	-10.42	-9.28	-12.40
Free Cash Flow	-9.23	-8.92	-6.72	-2.71	-2.35	-1.05
Free Cash Flow Per Share	-13.86	-13.73	-11.31	-5.60	-4.94	-2.66
EBITDA	-12.35	-14.85	-12.32	-	-	-
D&A For EBITDA	0.04	0.02	0	-	-	-
EBIT	-12.39	-14.87	-12.32	-4.95	-4.42	-5.01

Source: S&P Capital IQ. Standard template.